

DIA ADDRESSES **SAFETY TOPICS**

The 44th Annual Meeting of the Drug Information Association

Industry Thought Leaders Raise their VOICE at DIA



David Williams of Clinsys discusses what he believes the industry's biggest challenges are.



Imperial's Bob McGrath identifies risk mitigation as one of the biggest challenges facing the industry today.



Sheila Rocchio of PHT talks about the complexity of managing trials with fewer resources.



Dan Diaz from Beardsworth talks about the difficulties in patient enrollment.

DIA VIDEOS

Go to www.pharmavoice.com/editorstake and watch as these industry thought leaders speak candidly about industry trends, key take aways, and their biggest challenges.

ACTELION

Massimo Raineri

ACURIAN

Scott Connor

AUREUS RESEARCH CONSULTANTS

Alicia Pouncey

BEARDSWORTH

Thought Leader:
Dan Diaz

CLINLOGIX

JeanMarie Markham

CLINSYS

David Williams

CRF

Pamela McNamara

CRITERIUM

Kabelo Pududu

CRN

Gail Adinamis

D. ANDERSON & CO.

Melynda Geurts

DATATRIAL

Gill Hallet, M.Sc.

DSG

Tony Varano

ETRIALS

Michael Mickens

ICON

Suzanne Gagnon

IMPERIAL

Robert McGrath

INC RESEARCH

Alistair McDonald

INCLINIX

Tobin Geatz

INVENTIV CLINICAL SOLUTIONS

Dr. Scott Treiber

KENDLE

Dr. Janet Jones

KFORCE

Eleanore Doyle

MEDIDATA

Ed Seguiné

MEDPOINT COMMUNICATIONS

Bill Cooney

MICROSOFT

Michael Naimoli

MONITORFORHIRE

Scott Freedman

NEXTRIALS

James Rogers

OCTAGON

Jim Walker

(PI) PATIENT INTERACTION

Robert Loll

PATNI

Steve Jolley

PHT

Sheila Rocchio

PPD

James Streeter

PROTRIALS

Jodi Andrews

RIGEL PHARMACEUTICALS

Theresa Kane Musser

SAFE-BIOPHARMA ASSOCIATION

Mollie Shields Uehling

TECHTEAM

Joanna Gutkowski

WYETH


Dr. William Jacobson



Alistair McDonald of INC Research identifies what's hot in trials today.



Rigels' Theresa Kane Musser provides insights on her DIA experience.



Inclinx's Tobin Geatz discusses clinical development challenges.



Dr. Janet Jones of Kendle explores global issues.

THE 44TH ANNUAL MEETING OF THE DRUG INFORMATION ASSOCIATION in Boston from June 22-26, 2008, featuring 368 sessions, more than 1,100 speakers, and more than 850 exhibitors was the largest conference in the DIA's history. The meeting drew 8,900 attendees from 56 countries representing Asia, Africa, North America, South America, Europe, and Australia, as well as 50 representatives from academic institutions around the world.

"This year we received the largest ever number of abstracts for the annual meeting," notes Annual Meeting Program Chair Jeffrey Sherman, M.D., FACP. "The genuinely amazing educational content delivered at the Annual Meeting reinforces the importance of the DIA volunteers who helped prepare or instruct every session and tutorial."

This year's event included keynote addresses by Dennis Ausiello, M.D., Jackson Professor of Clinical Medicine at Harvard Medical School and Chief of Medicine at Massachusetts General Hospital, and Kathy Giusti, founder and CEO, Multiple Myeloma Research Foundation and Multiple Myeloma Research Consortium.

Speakers from U.S. and European regulatory agencies, the Regan-Udall Foundation, PhRMA, and other organizations discussed their goals and experiences with the FDA Amendments Act of 2007 (FDAAA) and its impact on drug safety.

Global drug development was a key focus of the annual meeting; attendees could choose from more than 100 sessions on issues affecting key regions of the world.

"DIA needs to continue to grow globally and to better meet its members' needs in the areas of information exchange, education, and networking opportunities, especially in pharma's emerging markets," says Linda McGoldrick, DIA Worldwide executive director. "Furthering this globalization initiative, the annual meeting featured more than 50 representatives from academic institutions around the world, and more than 100 sessions on topics important to markets such as Canada, Japan, Europe, Russia, Taiwan, Vietnam, Latin America, India, and China."

This year's program committee created megatracks in clinical research and information technology to enhance the quality of the presentations and their relevance to the challenges faced by today's clinical research and information technology professionals. ♦

PharmaVOICE welcomes comments about this article. E-mail us at feedback@pharmavoice.com.

The 2008 DIA Annual Meeting

The 44th Annual Meeting in Boston was the largest event in DIA history. The DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical, and regulatory industries worldwide.



1. More than 850 exhibitors, the most ever, gathered in Boston at DIA's 44th Annual Meeting. 2. Alicia Pouncey of Aureus Research Consultants and JeanMarie Markham of Clinlogix take a moment to catch up at PharmaVOICE's booth. 3. inVentiv encourages attendees to rev their engines during the conference. 4. Robert Loll of (PI) Patient Interaction stops by to say hello to the PharmaVOICE team. 5. DIA was front and center during the conference. 6. Quintiles was one of a wide range of companies exhibiting at this year's meeting. 7. A lucky winner of a Garmin receives her prize from Lisa Banket, publisher of PharmaVOICE.